Kodiak Sciences Inc (KOD)vsEli Lilly and Company (LLY)
KOD
Kodiak Sciences Inc
$35.94
-9.10%
HEALTHCARE · Cap: $2.13B
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
KOD
Avoid25
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Trading at 19.9x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KOD
KOD has a balanced fundamental profile.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : KOD
The primary concerns for KOD are Price/Book, Revenue Growth, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
KOD profiles as a value stock while LLY is a growth play — different risk/reward profiles.
KOD carries more volatility with a beta of 2.21 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 25/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kodiak Sciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?